Literature DB >> 9057081

L-arginine enhances functional recovery and Ca(2+)-dependent nitric oxide synthase activity after ischemia and reperfusion in the rat heart.

Q D Wang1, E Morcos, P Wiklund, J Pernow.   

Abstract

The effects of L-arginine on ischemia/reperfusion-induced myocardial dysfunction as well as the tissue activity of nitric oxide synthase (NOS) were investigated in rat isolated Langendorff-perfused hearts. Hearts were subjected to nonischemic perfusion or 30 min of global ischemia followed by 30 min of reperfusion. The hearts subjected to ischemia/reperfusion received either vehicle, L-arginine (1 mM), D-arginine (1 mM), the NOS inhibitor NG-nitro-L-arginine (L-NNA, 1 mM), or L-arginine (1 mM) plus L-NNA (1 mM) at the beginning of ischemia. L-Arginine but not D-arginine significantly enhanced the recoveries of left ventricular double product and coronary flow compared with the vehicle group. There was a substantial activity of Ca(2+)-dependent NOS but no significant Ca(2+)-independent NOS activity in the hearts undergoing 60 min of nonischemic perfusion. After ischemia/reperfusion, Ca(2+)-dependent NOS activity significantly decreased (by > 90%) in comparison with that of nonischemic hearts. L-Arginine increased the Ca(2+)-dependent NOS activity compared with the vehicle group to a level that was similar to that observed in nonischemic hearts. There was no difference in Ca(2+)-dependent NOS activity between vehicle- and D-arginine-treated groups. Administration of L-NNA abolished the beneficial effects of L-arginine on functional recovery and on Ca(2+)-dependent NOS activity. There were no significant Ca(2+)-independent NOS activities in any of the ischemic groups. These results suggest that myocardial ischemia/reperfusion reduces Ca(2+)-dependent NOS activity in the heart. Administration of L-arginine enhances myocardial function and preserves Ca(2+)-dependent NOS activity after ischemia/reperfusion through a pathway involving NOS activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9057081     DOI: 10.1097/00005344-199702000-00020

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Ticagrelor mitigates ischaemia-reperfusion induced vascular endothelial dysfunction in healthy young males - a randomized, single-blinded study.

Authors:  Stefan Weisshaar; Brigitte Litschauer; Matthias Eipeldauer; Eva Luise Hobl; Michael Wolzt
Journal:  Br J Clin Pharmacol       Date:  2017-08-22       Impact factor: 4.335

2.  The role of nitric oxide, superoxide and peroxynitrite in the anti-arrhythmic effects of preconditioning and peroxynitrite infusion in anaesthetized dogs.

Authors:  Attila Kiss; László Juhász; György Seprényi; Krisztina Kupai; József Kaszaki; Agnes Végh
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

3.  Influence of L-arginine on the expression of eNOS and COX2 in experimental pulmonary thromboembolism.

Authors:  Jianchu Zhang; Lei Xia; Xiaoju Zhang; Weibing Yang; Ming Bai
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

Review 4.  Peroxynitrite in myocardial ischemia-reperfusion injury.

Authors:  Manoj M Lalu; Wenjie Wang; Richard Schulz
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

5.  Sepiapterin reduces postischemic injury in the rat heart.

Authors:  Christiane P Tiefenbacher; Ching-Hua Lee; Jolanthe Kapitza; Volker Dietz; Feraydoon Niroomand
Journal:  Pflugers Arch       Date:  2003-08-05       Impact factor: 3.657

6.  Cardioprotective activity of iron oxide nanoparticles.

Authors:  Fei Xiong; Hao Wang; Yidong Feng; Yunman Li; Xiaoqing Hua; Xingyun Pang; Song Zhang; Lina Song; Yu Zhang; Ning Gu
Journal:  Sci Rep       Date:  2015-02-26       Impact factor: 4.379

7.  Protective effect of N-acetylcysteine activated carbon release microcapsule on myocardial ischemia-reperfusion injury in rats.

Authors:  Zhaobin Cai; Tingting Shi; Rangxiao Zhuang; Hongying Fang; Xiaojie Jiang; Yidan Shao; Hongping Zhou
Journal:  Exp Ther Med       Date:  2017-12-18       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.